[{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Endocyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2020","type":"Agreement","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotope Technologies Munich \/ Endocyte","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ Endocyte"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Indigenous Critical Infrastructure Fund Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Isotope Technologies Munich \/ Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"University Hospital Muenster","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Isotope Technologies Munich \/ University Hospital Muenster","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ University Hospital Muenster"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"177-Lu DOTA","moa":"||GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ Y-mAbs Therapeutics"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Agreement","leadProduct":"225-Ac Satoreotide Tetraxetan","moa":"SST2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Ariceum Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"BAMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Isotope Technologies Munich \/ BAMF","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ BAMF"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Technical University of Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Isotope Technologies Munich \/ Technical University of Munich","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Technical University of Munich"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"ANSTO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"No-carrier-added 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ ANSTO","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ ANSTO"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Paul Scherrer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Terbium-161","moa":"Beta-radiation\/auger electron","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Paul Scherrer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Paul Scherrer Institute"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"177-Lu","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Licensing Agreement","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2023","type":"Agreement","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Point Biopharma"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2020","type":"Agreement","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Point Biopharma"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Alpha-9 Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Alpha-9 Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Alpha-9 Oncology"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2024","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory"}]
Find Clinical Drug Pipeline Developments & Deals by Isotope Technologies Munich
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
